Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133(+) cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133(+) cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133(+) into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133(+) manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133(+) cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133(+) cell as an anti-ischemic AMP.
The CD133(+) Cell as Advanced Medicinal Product for Myocardial and Limb Ischemia / D., Bongiovanni; B., Bassetti B; E., Gambini; G., Gaipa; Frati, Giacomo; F., Achilli; P., Scacciatella; C., Carbucicchio; G., Pompilio. - In: STEM CELLS AND DEVELOPMENT. - ISSN 1547-3287. - STAMPA. - 23:(2014), pp. 2403-2421. [10.1089/scd.2014.0111]
The CD133(+) Cell as Advanced Medicinal Product for Myocardial and Limb Ischemia.
FRATI, GIACOMO;
2014
Abstract
Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133(+) cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133(+) cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133(+) into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133(+) manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133(+) cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133(+) cell as an anti-ischemic AMP.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.